Northern Capital Management (Wisconsin)’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Northern Capital Management (Wisconsin)’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-152,300	Closed	-$192K	–	164
2017 Q3	$192K	Buy	152,300 +46,250	+44%	+$59.1K	0.06%	148
2017 Q2	$141K	Buy	106,050 +80,675	+318%	+$117K	0.05%	148
2017 Q1	$47K	Sell	25,375 -10,575	-29%	-$47.8K	0.02%	142
2016 Q4	$186K	Hold	35,950	–	–	0.08%	135
2016 Q3	$200K	Buy	+35,950	New	+$205K	0.09%	132

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Northern Capital Management (Wisconsin)'s GNMX Position: Q4 2017 in Review

Northern Capital Management (Wisconsin) sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 152,300 shares — an estimated $192K sold.

Northern Capital Management (Wisconsin) first reported a position in GNMX in Q3 2016 and held it in 5 quarters. The position peaked at $200K in Q3 2016. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

Northern Capital Management (Wisconsin) reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
Northern Capital Management (Wisconsin) sold 152,300 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $192K.
Northern Capital Management (Wisconsin) first reported a position in Aevi Genomic Medicine Inc in Q3 2016 and held it in 5 quarters.
Northern Capital Management (Wisconsin)'s Aevi Genomic Medicine Inc position peaked at $200K in Q3 2016.
45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on Northern Capital Management (Wisconsin)'s 13F filing for Q4 2017, filed 30 Jan 2018.